Knee injection shows promise for regrowing cartilage in osteoarthritis
NCT ID NCT03275064
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested an experimental protein called LNA043, given as injections into the knee, to see if it can help regrow cartilage in people with knee osteoarthritis or cartilage injuries. 142 adults participated in two parts: one for cartilage lesions and one for osteoarthritis. The goal was to check safety and whether the treatment improves cartilage quality and volume on MRI scans.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- LNA043 (a protein injection into the knee joint)
- What this could lead to
- If successful, this could point toward a treatment that helps regrow knee cartilage, potentially reducing pain and delaying the need for joint replacement.
- What could go wrong
- This is an early Phase 2 trial with only 142 participants, so results may not apply to everyone. The treatment involves multiple injections and may not work for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
142 people
The number who actually took part.
- Started
-
Sep 2017
- Finished
-
Sep 2022
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria Part A * Patient was ≥18 and ≤55 years old at time of screening. * Patient had a body mass index (BMI) \<30 kg/m2 at screening, * Patient had a symptomatic, single, articular cartilage defect of one knee, grade II or IIIA according to the ICRS classification, localized to either the femoral condyles/femoral trochlea or to the patella, based on MRI or arthroscopy performed within 9 months before screening visit and confirmed by screening 3T MRI. * Patient had an onset of pain and impairment of function between two (2) months and two (2) years before screening. * Patient had a grade 2 or 3 OA of the knee with Joint Space Width (JSW) 2-4 mm evaluated with X-Ray at screening Inclusion criteria Part B * Patient was ≥18 and ≤75 years old at time of screening. * Patient had a body mass index (BMI) ≤ 35 kg/m2 at screening * Diagnosis of femorotibial osteoarthritis (OA) in the target knee by standard American College of Rheumatology (ACR) criteria at study start (clinical AND radiographic criteria) * Patient must have had symptomatic disease predominantly in one (the index) knee, with minimal or no symptoms in the contralateral knee. Symptomatic disease is defined as having pain in the knee more than 50% of the days during the last 3 months from screening. * Patient had a K\&L grade 2 or 3 OA of the knee with JSW 2.00-4.00 mm (X=0.225) fixed position evaluated with X-Ray by the Central Reader at screening. Exclusion criteria Part A \& B * Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 15 days after stopping of investigational drug. * Patient had surgical treatment of the target knee using mosaicplasty, microfracture, meniscectomy \>50% (Note: prior diagnostic arthroscopy with debridement and lavage, \<50% meniscectomy, lateral release, patellar realignment, medial patellofemoral ligament reconstruction are acceptable if performed at least 2 months prior to screening; anteriorcruciate ligament reconstrucion is acceptable if performed 12 months prior to screening, or less if restoration of joint function is evident, and agreed by the sponsor). * Patient had an unstable target knee joint or insufficiently reconstructed ligaments based on medical history and physical examination by the investigator. * Prohibited medication updated with reference to dosing (formerly screening). Exclusion Criteria Part A only * Regular smokers (\> 5 cigarettes/day). Urine cotinine levels will be measured during screening for all patients. Regular smokers will be defined as any patient who reports tobacco use of \> 5 cigarettes/day and/or who has a urine cotinine ≥ 500 ng/mL. * Patient had radiologically apparent degenerative joint disease in the target knee as determined by Kellgren and Lawrence grade ≥2 based on X-ray evaluation performed within 9 months from screening. * Patient had patellofemoral dysplasia Dejour Grade B-D based on X-ray evaluation performed within 9 months from screening * Patient had malalignment (valgus- or varus-deformity) in the target knee ≥ 5° based on X-ray evaluation performed within 9 months from screening. In suspected cases, the mechanical axis must be established radiographically through complete leg imaging during standing and in postero-anterior (PA) projection. Exclusion Criteria Part B only * Regular smokers (\> 10 cigarettes/day). * Clinical signs of inflammation (i.e., redness) in the target knee. * History of knee replacement (unilateral or total) in either knee. * Presence of severe hip OA conditioning lower limb function according to PI's evaluation. * Nephrotic syndrome and/or significant proteinuria * History of coagulopathy or medical condition requiring anticoagulation which would preclude knee injection * Patient had malalignment (valgus- or varus-deformity) in the target knee ≥ 7.5° based on X-ray evaluation. In suspected cases, the mechanical axis must be established radiographically through complete leg imaging during standing and in postero-anterior (PA) projection.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Articular cartilage lesion of the knee are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Arizona Research
Phoenix, Arizona, 85053, United States
-
Clinical Research of West Florida Inc
Tampa, Florida, 33606, United States
-
LV Research
Las Vegas, Nevada, 89119, United States
-
Midwest Orthopedics At Rush
Chicago, Illinois, 60612, United States
-
Northern California Research
Sacramento, California, 95821, United States
-
Novartis Investigative Site
Brno, Czech Republic, 66250, Czechia
-
Novartis Investigative Site
Mladá Boleslav, Czech Republic, 29301, Czechia
-
Novartis Investigative Site
Kladno, 272 59, Czechia
-
Novartis Investigative Site
Kolín, 280 02, Czechia
-
Novartis Investigative Site
Pardubice, 53002, Czechia
-
Novartis Investigative Site
Prague, 190 00, Czechia
-
Novartis Investigative Site
Aarhus N, 8200, Denmark
-
Novartis Investigative Site
Hvidovre, 2650, Denmark
-
Panax Clinical Research
Miami Lakes, Florida, 33014, United States
-
Precision Clinical Research LLC
Sunrise, Florida, 33351, United States
-
Scott A Hacker MD Medical Group d b a Horizon Clinical Res
La Mesa, California, 91942, United States
-
St Lukes Intermountain Research Center
Boise, Idaho, 83702, United States
-
Sundance Clinical Research LLC
St Louis, Missouri, 63141, United States
-
Temple University
Philadelphia, Pennsylvania, 19140, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Custom knee guides put to the test in obese patients
- Can a shot of your own blood ease arthritic knees?
- 5,000 knee arthritis patients tracked to crack the treatment code
- Can a hydrogel injection ease knee arthritis pain?
- Weekly shot aims to melt away pounds in obesity fight
- Can shockwave plus injections quiet knee arthritis pain?